Imatinib mesylate (Gleevec [Glivec], Novartis), a protein kinase inhibitor of c-kit receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor α (PGFR-α), is widely used for the ...

In a total of 532 patients with chronic phase CML treated with 400 mg of imatinib mesylate daily, 32% were reported with a rash or related event. 5 Skin adverse events were also documented in a ...

She was known to have the activation-loop mutation H396R, which is associated with resistance to imatinib. 1 She entered a phase 2 trial of dasatinib (BMS-354825, Bristol-Myers Squibb), a new ...

A dose of 400 mg imatinib twice daily improves progression-free survival compared with a once-daily dose, with similar rates of response and adverse events.

In patients with chronic myeloid leukemia, front-line high-dose imatinib showed a rapid response and a trend toward a higher major molecular response at 12 months, although the improvement was not ...

The FDA expanded indications for imatinib mesylate tablets (Gleevec, Novartis) to include patients who have had CD117-positive gastrointestinal stromal tumors surgically removed.

Consumer Medicine Information (CMI) about Imatinib-Teva intended for persons living in Australia. Skip to content. ... vomiting, diarrhoea, constipation, rash, eczema, itchy or dry skin, ...

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

Imatinib mesylate, also known as Gleevec, is showing early signs of promise in preclinical trials against Ewing's sarcoma, a bone tumor in children and adolescents. In a study in the November 20 ...

Karimi M, Bahadoram M, Mafakher L, Rastegar M. Impact of imatinib on reducing the painful crisis in patients with sickle cell disease. Hematol Transfus Cell Ther . Published online August 10, 2023 ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.